Clinical evaluation of once-weekly and three-times-weekly dosings of epoetin alfa in chemotherapy patients: Problems of study design and interpretation [2]

Journal of Clinical Oncology

Volumn 20, Issue 3, 2002, Pages 878-

  Nguyen, Tuan V ^a   Trinh, Giang N ^a  

^a Methodist Healthcare   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; FOLLOW UP; HEMATOLOGIC DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036467831     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2002.20.3.878     Document Type: Letter

References (2)

1. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
2. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response tumor type: Results from a prospective community oncology study